AbbVie announced its financial results for the second quarter of 2025, reporting a diluted earnings per share (EPS) of $0.52 on a GAAP basis, a decrease of 32.5%, while adjusted diluted EPS increased by 12.1% to $2.97. The company achieved net revenues of $15.423 billion, marking a 6.6% increase. Key contributors to revenue included the immunology portfolio, which generated $7.631 billion, and the neuroscience portfolio, which brought in $2.683 billion. However, revenues from the aesthetics portfolio decreased by 8.1% to $1.279 billion, driven by declines in Botox Cosmetic and Juvederm sales. AbbVie also raised its adjusted diluted EPS guidance for the full year to a range of $11.88 to $12.08, which accounts for an unfavorable impact of $0.55 per share from acquired IPR&D and milestones expenses incurred year-to-date through Q2 2025.
Recent developments included FDA approvals for Rinvoq and Emrelis, as well as positive results from clinical trials for several products, including Qulipta and Rinvoq in new indications. AbbVie also announced its acquisition of Capstan Therapeutics, which will enhance its pipeline with a potential first-in-class therapy for autoimmune diseases. The company continues to advance its oncology portfolio, with significant progress reported at the ASCO Annual Meeting. Despite a recent setback with the VERONA trial for Venclexta, AbbVie remains focused on innovation and expanding its therapeutic offerings across various medical fields.
linkJul 31, 2025 07:48:24
AbbVie anticipates a pre-tax expense of $823 million related to acquired IPR&D and milestones for the second quarter of 2025, which is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.42. The company has not finalized its results for the quarter ending June 30, 2025, and these preliminary estimates may change as financial statement closing procedures are completed.
For the full year 2025, AbbVie has updated its adjusted diluted earnings per share guidance to a range of $11.67 to $11.87, incorporating the anticipated second quarter expenses. The adjusted diluted earnings per share guidance for the second quarter is projected to be between $2.84 and $2.88, excluding any additional expenses from acquired IPR&D and milestones that may occur later in the year.
linkJul 03, 2025 13:07:55
AbbVie Inc. has updated its earnings per share (EPS) guidance for the second quarter and full year of 2025, reflecting the impact of acquired in-process research and development (IPR&D) and milestones expense. For Q2 2025, the adjusted diluted EPS is now projected to be between $2.84 and $2.88, after accounting for an expense of $823 million. This is a decrease from the previously announced guidance that did not include these expenses.
For the full year 2025, the adjusted diluted EPS guidance is now set between $11.67 and $11.87, with the same $823 million expense factored in. The guidance excludes any further IPR&D and milestones expenses that may arise after Q2 2025, as these costs cannot be reliably predicted at this time.
linkJul 03, 2025 13:07:55
AbbVie announced its financial results for the first quarter of 2025, reporting a diluted earnings per share (EPS) of $0.72 on a GAAP basis, which is a decrease of 6.5%. However, the adjusted diluted EPS increased by 6.5% to $2.46. The company achieved net revenues of $13.343 billion, reflecting an 8.4% increase from the previous year. The immunology portfolio saw significant growth, with global net revenues of $6.264 billion, while the aesthetics portfolio experienced a decline of 11.7% in net revenues to $1.102 billion. AbbVie raised its adjusted diluted EPS guidance for the full year 2025 to a range of $12.09 to $12.29, factoring in an unfavorable impact from acquired expenses.
In recent developments, AbbVie announced the election of CEO Robert A. Michael as chairman of the board, effective July 1, 2025. The European Commission granted marketing authorization for Rinvoq to treat giant cell arteritis, and AbbVie reported positive trial results for Elahere in treating ovarian cancer. Additionally, the company has entered into a collaboration with Xilio Therapeutics for developing new immunotherapies and submitted a Biologics License Application for trenibotulinumtoxinE. Furthermore, AbbVie has announced a license agreement with Gubra to develop a long-acting amylin analog for obesity treatment.
linkApr 25, 2025 07:48:22
AbbVie Inc. has updated its guidance for adjusted diluted earnings per share (EPS) for the first quarter and full year of 2025, incorporating expenses related to acquired IPR&D and milestones. For Q1 2025, the adjusted diluted EPS is now projected to be between $2.34 and $2.38, reflecting a decrease due to an expense of $248 million, which lowers the EPS by $0.13. For the full year, the adjusted diluted EPS guidance is set between $11.99 and $12.19, also accounting for the same expense.
The company noted that the updated guidance does not include any potential impact from future expenses related to acquired IPR&D and milestones that may occur beyond Q1 2025, as these cannot be reliably predicted. Additionally, the guidance does not take into account the effects of a licensing agreement with Gubra for the development of GUB014295, which was finalized after the first quarter of 2025.
linkApr 03, 2025 16:13:07
AbbVie has appointed CEO Robert A. Michael as chairman of the board, effective July 1, 2025, succeeding Richard A. Gonzalez, who has served in this role since the company's inception in 2013. The board expressed confidence in Michael's leadership, highlighting his extensive experience and contributions to AbbVie’s success, particularly in navigating the end of exclusivity for Humira in the U.S. Additionally, Glenn F. Tilton will retire from the board on the same date after serving as lead independent director from 2013 to 2024.
The transition in leadership comes as the company looks to build on its track record of success and continue delivering innovative medicines. While the press release emphasizes the positive aspects of the leadership change, it does not address any current financial challenges or market conditions that may impact AbbVie’s future performance. The absence of any mention of financial metrics or challenges suggests a focus on leadership continuity rather than a detailed financial outlook.
linkFeb 14, 2025 07:30:58
AbbVie announced a full-year net revenue of $56.334 billion, marking an increase of 3.7% on a reported basis. The company's immunology portfolio generated $26.682 billion, while the oncology and neuroscience portfolios saw significant growth, with revenues of $6.555 billion and $8.999 billion respectively. Notably, Skyrizi and Rinvoq contributed to this growth with revenues of $11.718 billion and $5.971 billion, reflecting increases of 49.3% and 50.8% respectively. The fourth-quarter results also showed a revenue increase of 5.6% to $15.102 billion, driven by the immunology and oncology sectors. Adjusted diluted EPS for the fourth quarter was reported at $2.16, despite a GAAP diluted loss per share of $0.02 due to impairment charges related to emraclidine.
Conversely, AbbVie faced challenges with the decline of Humira, which saw a significant drop in net revenues, decreasing by 49.1% to $1.682 billion in the fourth quarter. The aesthetics portfolio also experienced a downturn, with a reported revenue decrease of 5.2% to $1.298 billion. Additionally, the company recorded a substantial non-cash after-tax intangible asset impairment charge of $3.5 billion, reflecting the challenges faced in the development of emraclidine. Overall, while AbbVie demonstrated growth in several areas, the declines in key products and the impairment charge raised concerns about future performance.
linkJan 31, 2025 07:42:37
AbbVie Inc. has revised its earnings per share (EPS) guidance for the fourth quarter of 2024, factoring in a significant expense of $1.574 billion related to acquired in-process research and development (IPR&D) and milestone payments. This adjustment results in a projected adjusted diluted EPS range of $2.06 to $2.10 for the quarter, down from the previous guidance of $2.94 to $2.98 without these expenses. The full-year adjusted diluted EPS guidance has also been updated to a range of $10.02 to $10.06, reflecting the impact of these expenses on overall earnings for the year.
On the downside, the inclusion of the $1.574 billion expense leads to a notable decrease in the EPS projections compared to earlier estimates. The adjustment highlights the financial burden of the acquired IPR&D and milestone expenses, which may raise concerns among investors regarding the company's profitability for the upcoming quarter and year.
linkJan 06, 2025 16:02:39
AbbVie reported third-quarter 2024 net revenues of $14.460 billion, marking a 3.8 percent increase year-over-year. The company saw significant growth in its oncology and neuroscience portfolios, with respective revenue increases of 11.6 percent and 15.6 percent. The immunology portfolio also contributed positively, although Humira revenues decreased substantially. AbbVie successfully completed the acquisition of Cerevel, enhancing its neuroscience pipeline, and announced a dividend increase of 5.8 percent for 2025, reflecting its commitment to returning value to shareholders.
Conversely, the company faced challenges, particularly with Humira, which experienced a notable revenue decline of 37.2 percent. Additionally, while adjusted diluted EPS increased by 1.7 percent to $3.00, GAAP diluted EPS fell by 12.0 percent to $0.88. The acquisition-related expenses impacted earnings per share negatively. Overall, while AbbVie showed progress in several areas, the decline in Humira and the mixed performance across its portfolios highlighted ongoing challenges.
linkOct 30, 2024 07:43:14
AbbVie has updated its financial guidance for the third quarter and full year of 2024, factoring in expenses related to acquired research and development. The adjusted earnings per share (EPS) for Q3 is now projected to be slightly lower, reflecting an expense of $82 million, which will reduce the EPS range by four cents. This indicates a cautious approach as the company navigates additional costs from its acquisitions.
Despite the adjustments, AbbVie's overall financial outlook remains stable, with the full-year adjusted EPS guidance still showing a strong range. The company is maintaining a positive stance, indicating confidence in its operations and future performance. However, the need to account for these expenses suggests that investors should be mindful of potential fluctuations in earnings as the company continues to integrate new assets.
linkOct 03, 2024 16:07:32